'''Edelfosine''' (ET-18-O-CH3; 1-octadecyl-2-''O''-methyl-glycero-3-phosphocholine)<ref name=R2008>{{cite journal|url=http://apjcn.nhri.org.tw/server/APJCN/Volume17/vol17suppl.1/204-207S12-1.pdf |title=The antitumor ether lipid Edelfosine (ET-18-O-CH3) induces apoptosis in H-ras transformed human breast epithelial cells: by blocking ERK1/2 and p38 mitogenactivated protein kinases as potential targets |year=2008 |deadurl=yes |archiveurl=https://web.archive.org/web/20110811144708/http://apjcn.nhri.org.tw/server/APJCN/Volume17/vol17suppl.1/204-207S12-1.pdf |archivedate=2011-08-11 |df= }}</ref> is a synthetic [[alkyl-lysophospholipids|alkyl-lysophospholipid]] (ALP).  It has [[antineoplastic]] (anti-cancer) effects.<ref>{{cite journal | pmid = 9844614 | volume=16 | issue=8 | title=The anticancer drug edelfosine is a potent inhibitor of neovascularization in vivo | year=1998 | pages=549–53 | journal=Cancer Invest. | doi=10.3109/07357909809032884}}</ref>

 
Like all ALPs, it incorporates into the [[cell membrane]] and does not target the [[DNA]]. In many tumor cells, it causes selective [[apoptosis]], sparing healthy cells.<ref name=Mollinedo-2002>{{cite journal|last=Gajate|first=C|author2=Mollinedo F|title=Biological Activities, Mechanisms of Action and Biomedical Prospect of the Antitumor Ether Phospholipid ET-18-OCH3 (Edelfosine), A Proapoptotic Agent in Tumor Cells.|journal=Current Drug Metabolism|year=2002|volume=5|issue=3|pages=491–525|doi=10.2174/1389200023337225}}</ref>  Edelfosine can activate the [[Fas receptor|Fas]]/[[CD95]] cell death receptor,<ref name=Mollindeo-2004>{{cite journal|last=Mollinedo|first=F |author2=Gajate C |author3=Martín-Santamaria S |author4=Gago F|title=ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor.|journal=Current Medicinal Chemistry|year=2004|volume=11|issue=24|pages=3163–84|pmid=15579006|doi=10.2174/0929867043363703}}</ref> can inhibit the [[MAPK/ERK]] mitogenic pathway and the [[Akt]]/[[protein kinase B]] (PKB) survival pathway.<ref name=Mollinedo-2002 /><ref name=Ruiter-2003>{{cite journal|last=Ruiter|first=GA|author2=Zerp SF |author3=Bartelink H |author4=Blitterswijk WJ van |author5= Verheij M |title=Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway.|journal=Anti-Cancer Drugs|year=2003|volume=14|issue=2|pages=167–73|pmid=12569304|doi=10.1097/01.cad.0000054974.31252.f7}}</ref>  Aside from these plasma-level effects, edelfosine also affects gene expression by modulating the expression and activity of transcription factors.<ref name=Mollinedo-2002 /><ref name=Mollindeo-2004 />

 
It has immune modulating properties.<ref>{{cite journal|last=Munder|first=PG|author2=Modolell M |author3=Andreesen R |author4=Weltzien HU |author5= Westphal O |title=Lysophosphatidylcholine ( Lysolecithin ) and its Synthetic Analogues. Immunemodulating and Other Biologic Effects |journal=Springer Seminars in Immunopathology|year=1979|volume=203|pages=187–203 |doi=10.1007/bf01891668}}</ref>  

 
In animal tests the main toxic effect was gastrointestinal irritation. There were no significant negative systemic side effects observed. It showed that edelfosine can be given over a long period safely. Most important, in contrast to many DNA-directed anti-cancer drugs, no bone marrow toxicity was ''in vivo'' observed. Those findings in animals were confirmed in clinical trials.  No mutagenic or cytogenetic effects were observed.<ref name=Mollinedo-2002 /><ref name=Houlihan-1995>{{cite journal|last=Houlihan|first=WJ|author2=Lohmeyer M |author3=Workman P |author4= Cheon SH |title=Phospholipid antitumor agents.|journal=Medicinal Research Reviews.|year=1995|volume=15|issue=3|pages=157–223|pmid=7658750|doi=10.1002/med.2610150302}}</ref>
